To assess the efficacy of escitalopram combined with quetiapine vs quetiapine alone in the treatment of depressive episodes of bipolar disorder (BPD).
Methods
Eighty-eight hospitalized patients with a BPD depressive episode were recruited into the study. All patients were randomized to a control group (n = 44) or the intervention group (n = 44). Members of the control group received quetiapine fumarate alone, with an initial dose 50 mg twice/day; the dose was increased by 50-100 mg daily until 300-600 mg/d was reached. The treatment group received quetiapine at the same doses plus escitalopram, with the initial dose of escitalopram 10 mg/d, adjusting the dose to 20 mg/d after 1 week. Both groups were treated for 8 weeks. Scores on the Hamilton Depression Scale (HAMD) and Young Mania Rating Scale (YMRS), along with levels of IL-6, IL-1β, MIF, SOD, CAT, MDA and GSH-Px, were compared between groups.
Results
Among those in the intervention group, 88.6% of participants experienced a 50% or greater reduction in HAMD score compared to 70.5% in the control group (P < .05). Participants in the intervention group also experienced a significantly greater reductions in IL-6, IL-1β, MIF and MDA levels (P < .05), and a significant increase in SOD, CAT and GSH-Px levels compared to the control group (P < .05).
Conclusion
Escitalopram oxalate combined with quetiapine is more effective than quetiapine alone in the treatment of patients with bipolar depressive episodes. This combination can effectively improve the symptoms of depression, inhibit the body’s inflammatory response, regulate the state of oxidative stress, and does not increase the risk of mania.
HuberRSDouglasKMSperrySH, et al.The early mid-career committee (EMCC) of the international society for bipolar disorders: aspirations and goals. Bipolar Disord. 2022;24(8):781-783. doi:10.1111/bdi.13269.
DembekCMackieDModiKZhuYNiuXGrinnellT. The economic and humanistic burden of bipolar disorder in adults in the United States. Ann Gen Psychiatr. 2023;22(1):13. doi:10.1186/s12991-023-00440-7.
4.
GaoKSuMSweetJCalabreseJR. Correlation between depression/anxiety symptom severity and quality of life in patients with major depressive disorder or bipolar disorder. J Affect Disord. 2019;244:9-15. doi:10.1016/j.jad.2018.09.063.
5.
Van BergenAHVerkooijenSVreekerA, et al.The characteristics of psychotic features in bipolar disorder. Psychol Med. 2019;49(12):2036-2048. doi:10.1017/S0033291718002854.
6.
WozniakJFarrellADiSalvoM, et al.A randomized, double-blind, controlled clinical trial of omega-3 fatty acids and inositol as monotherapies and in combination for the treatment of pediatric bipolar spectrum disorder in children age 5-12. Psychopharmacol Bull. 2022;52(4):31-51.
7.
WangZCaoYZhuY, et al.Differences in demographic and clinical characteristics of patients with depressive vs. manic first episode of bipolar disorder. Front Psychiatr. 2021;12:616415. doi:10.3389/fpsyt.2021.616415.
KanbaSMurasakiMKoyamaT, et al.Long-term mood/antidepressant effects of quetiapine extended-release formulation: an open-label, non-controlled extension study in Japanese patients with bipolar depression. BMC Psychiatr. 2019;19(1):198. doi:10.1186/s12888-019-2181-9.
10.
BartoliFBachiBCalabreseA, et al.Effect of long-acting injectable antipsychotics on emergency department visits and hospital admissions in people with bipolar disorder: a retrospective mirror-image analysis from the Northern Milan area cohort (NOMIAC) study. J Affect Disord. 2022;318:88-93. doi:10.1016/j.jad.2022.08.096.
11.
RashidMRahmanMKhanMF. Phenothiazines and related antipsychotic drugs. Med Chem of Drugs Aff the Nervous Sys. 2020;2:109-162.
12.
El-KhaliliNJoyceMAtkinsonS, et al.Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917-932. doi:10.1017/S1461145710000015.
13.
NestsiarovichAGaudiotCESBaldessariniRJVietaEZhuYTohenM. Preventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2022;54:75-89. doi:10.1016/j.euroneuro.2021.08.264.
14.
SerrettiA. Open issues in bipolar and antipsychotic treatments. Int Clin Psychopharmacol. 2022;37(6):231-233. doi:10.1097/YIC.0000000000000440.
15.
LinCCYangCPChengPYHsiaoMLiuYP. Escitalopram reversibility of the impacts following chronic stress on central 5-HT profiles - implications to depression and anxiety. Behav Brain Res. 2023;453:114613. doi:10.1016/j.bbr.2023.114613.
16.
AraiKNonakaMShimadaSNakamuraM. Vortioxetine as a potential alternative for patients with escitalopram-induced jitteriness/anxiety syndrome: a report of three cases. PCN Rep. 2023;2(4):e158.
17.
MandalPKGaurSRoyRGSamkariaAIngoleRGoelA. Schizophrenia, bipolar and major depressive disorders: overview of clinical features, neurotransmitter alterations, pharmacological interventions, and impact of oxidative stress in the disease process. ACS Chem Neurosci. 2022;13(19):2784-2802. doi:10.1021/acschemneuro.2c00420.
18.
FungVCOverhageLNSylviaLG, et al.Complex polypharmacy in bipolar disorder: side effect burden, adherence, and response predictors. J Affect Disord. 2019;257:17-22. doi:10.1016/j.jad.2019.06.050.
19.
CalabreseJRDurgamSSatlinA, et al.Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatr. 2021;178(12):1098-1106. doi:10.1176/appi.ajp.2021.20091339.
20.
MiolaATondoLBaldessariniRJ. Effects of treatment of acute major depressive episodes in bipolar I versus bipolar II disorders with quetiapine. J Clin Psychopharmacol. 2022;42(6):530-535. doi:10.1097/JCP.0000000000001601.
21.
PatelRSVeluriNPatelJPatelRMachadoTDilerR. Second-generation antipsychotics in management of acute pediatric bipolar depression: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol. 2021;31(8):521-530. doi:10.1089/cap.2021.0031.
22.
FornaroMStubbsBDe BerardisD, et al.Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials. Int J Mol Sci. 2016;17(2):241. doi:10.3390/ijms17020241.
23.
PatinoLRKleinCCStrawnJR, et al.A randomized, double-blind, controlled trial of lithium versus quetiapine for the treatment of acute mania in youth with early course bipolar disorder. J Child Adolesc Psychopharmacol. 2021;31(7):485-493. doi:10.1089/cap.2021.0039.
24.
AkkaouiMALejoyeuxMd’OrthoMPGeoffroyPA. Nightmares in patients with major depressive disorder, bipolar disorder, and psychotic disorders: a systematic review. J Clin Med. 2020;9(12):3990. doi:10.3390/jcm9123990.
25.
ZhangXMaXChengW, et al.Effects of escitalopram oxalate plus low-dose trazodone on psychological state and quality of life in patients with treatment-refractory depression. Am J Transl Res. 2023;15(3):1905-1912.
26.
OkadaMFukuyamaKMotomuraE. Dose-dependent biphasic action of quetiapine on AMPK signalling via 5-HT7 receptor: exploring pathophysiology of clinical and adverse effects of quetiapine. Int J Mol Sci. 2022;23(16):9103. doi:10.3390/ijms23169103.
27.
DivyashreeC. A comparative study of efficacy and safety of fluoxetine. In: Sertraline and Escitalopram in First Episode of Unipolar Depressive Disorder. Bengaluru, India: Rajiv Gandhi University of Health Sciences; 2019.
28.
FerrariMGodioMMartiniSCallegariCCosentinoMMarinoF. Inflammatory markers at baseline correlate with subsequent clinical response to quetiapine in patients with bipolar disorder. Hum Psychopharmacol. 2022;37(6):e2854. doi:10.1002/hup.2854.
29.
LimaDDCyrinoLARFerreiraGK, et al.Neuroinflammation and neuroprogression produced by oxidative stress in euthymic bipolar patients with different onset disease times. Sci Rep. 2022;12(1):16742. doi:10.1038/s41598-022-21170-y.
30.
SabouriSEsmailzadehMSadeghinejadAEslami ShahrbabakiMAsadikaramGNikvarzN. The effect of adjunctive probiotics on markers of inflammation and oxidative stress in bipolar disorder: a double-blind, randomized, controlled trial. J Psychiatr Pract. 2022;28(5):373-382. doi:10.1097/PRA.0000000000000660.
31.
BrownNCAndreazzaACYoungLT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatr Res. 2014;218(1-2):61-68. doi:10.1016/j.psychres.2014.04.005.
